🇺🇸 Epirubicine in United States

178 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 20 reports (11.24%)
  2. Vomiting — 20 reports (11.24%)
  3. Cardiac Failure — 19 reports (10.67%)
  4. Diarrhoea — 19 reports (10.67%)
  5. Nausea — 19 reports (10.67%)
  6. Ejection Fraction Decreased — 18 reports (10.11%)
  7. Neutropenia — 17 reports (9.55%)
  8. Acute Myeloid Leukaemia — 16 reports (8.99%)
  9. Pyrexia — 16 reports (8.99%)
  10. Febrile Neutropenia — 14 reports (7.87%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Epirubicine approved in United States?

Epirubicine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Epirubicine in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.